Hes5 siRNA treatment also increased expression of genes for myosin heavy chain 11 and smoothelin, suggesting that inactivation of Hes5-mediated signalling in PAH cells promotes phenotypic switching from a synthetic to a more contractile phenotype [11]. The gene discussed is SMTN; the disease is pulmonary arterial hypertension.